E.U. Court Advisor Rejects Bid To Close Drug Loophole

Law360, New York (January 23, 2007, 12:00 AM EST) -- A senior legal adviser to Europe's highest court has tossed a bid by pharmaceutical companies to close a legal loophole that allowed a Portuguese generic drug maker to produce a copycat version of one of Merck & Co.'s blood-pressure drugs whose 15-year patent protection had expired.

Under the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement, drug originators enjoy the right to a 20-year monopoly on their inventions. (The European Union signed on to that agreement in 1994.)

Before TRIPS, many countries provided only 15 years...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.